Orthofix International Maps Steady Growth After Earnings

Orthofix International ((OFIX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Orthofix International’s latest earnings call struck a cautiously upbeat tone, emphasizing operational gains and disciplined execution despite several near‑term headwinds. Management highlighted strong growth in core spine and limb businesses, improving margins and cash generation, while acknowledging pricing, distributor transition and legal overhangs that temper the short‑term outlook but not the medium‑term growth story.

Steady Top-Line Performance in Q4

Orthofix reported total global net sales of $218.6 million in the fourth quarter, representing 3% pro‑forma growth when adjusted for constant currency and excluding the divested M6 disc business. The growth rate is modest, but it reflects resilience in the company’s core franchises as management retools the commercial channel and reallocates focus toward higher‑performing segments.

Spine Fixation Growth and Channel Realignment

Spine Fixation remained a standout, with global sales up 10% for the full year and U.S. Spine growing 6% for the year and 5% in Q4. The company’s distribution overhaul is taking hold, as the top 30 U.S. distributor partners grew net sales 25% year over year and now drive more than 75% of U.S. revenue, up roughly 55 percentage points since the start of 2024.

Bone Growth Therapies Outpacing the Market

Bone Growth Therapies delivered one of the strongest performances, with Q4 net sales rising 7%, more than double the estimated 2–3% market growth. Management cited higher utilization and faster prescribing across spine fusion and fracture management, suggesting Orthofix is gaining share in a key recurring‑revenue category.

Limb Reconstruction Maintains Strong Momentum

The Limb Reconstruction business continued to build momentum, with U.S. sales up 8% in Q4 and 16% for the full year. Growth was supported by recent launches such as TrueLok Elevate and FITBONE bone transport and trochanteric lengthening nails, underscoring the benefits of a focused portfolio strategy in complex orthopedics.

Enabling Technologies Gain Commercial Traction

Orthofix’s enabling technologies also showed traction, as 7D FLASH navigation placements rose about 30% in 2025. The Voyager earnout model is proving effective, with placements up 30% and earnout customers purchasing more than 50% above their committed volumes, validating both utilization and the company’s structure for technology adoption.

Margin Expansion and EBITDA Growth Continue

Profitability trends were a key highlight, with Q4 pro‑forma non‑GAAP adjusted gross margin reaching 71.4%. Adjusted EBITDA was $29.2 million, or 13.4% of net sales, reflecting roughly 230 basis points of margin expansion year over year and marking the eighth straight quarter of adjusted EBITDA growth for the company.

Improving Free Cash Flow and Solid Liquidity

Cash generation improved meaningfully, as Orthofix posted strong Q4 free cash flow of $16.8 million. For the full year, free cash flow excluding M6‑related restructuring totaled $3.1 million, and the company ended the period with $85.1 million in cash, providing liquidity to support ongoing investments and product launches.

Robust Pipeline and VIRATA Launch Roadmap

Management outlined a busy product roadmap, including more than a dozen launches and upgrades over the next 18 months. A key milestone will be the full market release of the VIRATA Spinal Fixation System in the second half of 2026, targeting the roughly $2 billion U.S. pedicle screw market and complemented by an earlier MIS alpha launch and enhancements in Limb Reconstruction and BGT.

Distributor Transitions Pressure Near-Term Results

The company’s aggressive distributor transition strategy has created short‑term friction, including variable access to certain integrated delivery network accounts. These disruptions weighed on near‑term performance and led management to extend its long‑range plan timeline by one year, pushing out the full realization of channel benefits but supporting a more durable structure.

Biologics Weakness and Channel Disruption

Biologics posted a softer quarter, with management pointing to channel disruption from the distributor changes and deliberate strategic shifts in the portfolio. The segment is being refocused, but a recovery in this business is needed to fully unlock Orthofix’s growth potential, making it a watch point for investors over the next several quarters.

Moderate Growth Outlook and Pricing Headwinds

While several segments are performing well, overall growth remains moderate, with Q4 net sales up 3% and 2026 guidance implying about 5.5% pro‑forma growth. Comparisons are also weighed down by the annualized impact of a previously disclosed price decrease at a major account, which continues to pressure year‑over‑year metrics despite underlying volume gains.

BGT Headwind from CMS Pilot Program

Management flagged a temporary policy‑driven headwind for Bone Growth Therapies in the first quarter of 2026 from a CMS team pilot program. The impact is expected to reduce BGT revenue by roughly 1% in Q1 but is described as immaterial for the full year, mainly altering quarterly cadence rather than the underlying trajectory.

Free Cash Flow Seasonality and Higher CapEx

Even as full‑year free cash flow is expected to remain positive excluding legal settlements, management cautioned that 2025 will be close to breakeven and not every quarter will be in the black. Planned capital expenditures of $45–$50 million in 2026 will weigh on near‑term cash generation as the company funds technology capabilities and manufacturing scale‑up.

Legal, Tariff and Currency Risks Remain

The company has already taken an accrual for potential legal settlements, but guidance and free‑cash‑flow projections do not include any settlement outflows, leaving a clear downside risk to cash and earnings depending on timing and magnitude. Tariffs are expected to cost roughly $1–$2 million in 2026, and results remain exposed to foreign‑exchange volatility since guidance assumes current FX rates.

Guidance Underscores Gradual Growth and Margin Upside

For 2026, Orthofix guided to net sales of $850–$860 million, implying about 5.5% pro‑forma constant‑currency growth at the midpoint, along with non‑GAAP adjusted EBITDA of $95–$98 million and positive full‑year free cash flow excluding legal items. The company targets roughly 72.5% adjusted gross margin, about 70 basis points of EBITDA margin expansion weighted to the back half, mid‑single‑digit revenue growth in the first half and slightly higher growth in the second, and reaffirmed 2026–2028 goals for a 6.5–7.5% sales CAGR, mid‑teens EBITDA margins by 2028 and sustained positive free cash flow.

Orthofix’s earnings call painted a picture of a company in the middle of a strategic transition, with strengthening core businesses, expanding margins and improving cash flow offset by distribution, pricing and legal uncertainties. For investors, the story hinges on management executing its channel strategy, bringing the VIRATA and broader pipeline to market and delivering on its 2026–2028 margin and cash‑flow ambitions while navigating the near‑term risks.